Portal pressure responses and angiotensin peptide production in rat liver are determined by relative activity of ACE and ACE2

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 297, Issue 1, 2009, Pages

  Herath, Chandana B ^a   Lubel, John S ^a   Jia, Zhiyuan ^a   Velkoska, Elena ^a   Casley, David ^a   Brown, Lindsay ^b   Tikellis, Chris ^c   Burrell, Louise M ^a   Angus, Peter W ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Angiotensin converting enzyme; Angiotensin peptide metabolism; Hepatic fibrosis; Hepatic resistance; Neutral endopeptidase

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN[1-7]; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; MEMBRANE METALLOENDOPEPTIDASE; MLN 4760; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER METABOLISM; MALE; NONHUMAN; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRESSORECEPTOR; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT; REAL TIME POLYMERASE CHAIN REACTION;

ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANGIOTENSINS; ANIMALS; COMMON BILE DUCT; GENE EXPRESSION REGULATION, ENZYMOLOGIC; IMIDAZOLES; LEUCINE; LIGATION; LISINOPRIL; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; NEPRILYSIN; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; PORTAL PRESSURE; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RENIN-ANGIOTENSIN SYSTEM; SEVERITY OF ILLNESS INDEX; THIAZEPINES; TIME FACTORS; VASCULAR RESISTANCE;

EID: 67650074511     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00045.2009     Document Type: Article

References (39)

1. Acharya KR, Sturrock ED, Riordan JF, Ehlers MR. Ace revisited: a new target for structure-based drug design. Nat Rev Drug Discov 2: 891-902, 2003.
2. Ballet F, Chretien Y, Rey C, Poupon R. Differential response of normal and cirrhotic liver to vasoactive agents. A study in the isolated perfused rat liver. J Pharmacol Exp Ther 244: 283-289, 1988.
3. Bataller R, Gabele E, Schoonhoven R, Morris T, Lehnert M, Yang L, Brenner DA, Rippe RA. Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver. Am J Physiol Gastrointest Liver Physiol 285: G642-G651, 2003.
4. Benter IF, Yousif MH, Anim JT, Cojocel C, Diz DI. Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME. Am J Physiol Heart Circ Physiol 290: H684-H691, 2006.
5. Burchill L, Velkoska E, Dean RG, Lew RA, Smith AI, Levidiotis V, Burrell LM. Acute kidney injury in the rat causes cardiac remodelling and increases angiotensin-converting enzyme 2 expression. Exp Physiol 93: 622-630, 2008.
6. Campagnole-Santos MJ, Diz DI, Santos RA, Khosla MC, Brosnihan KB, Ferrario CM. Cardiovascular effects of angiotensin-(1-7) injected into the dorsal medulla of rats. Am J Physiol Heart Circ Physiol 257: H324-H329, 1989.
7. Chappell MC, Gomez MN, Pirro NT, Ferrario CM. Release of angiotensin-(1-7) from the rat hindlimb: influence of angiotensin-converting enzyme inhibition. Hypertension 35: 348-352, 2000.
8. Deddish PA, Marcic BM, Tan F, Jackman HL, Chen Z, Erdos EG. Neprilysin inhibitors potentiate effects of bradykinin on b2 receptor. Hypertension 39: 619-623, 2002.
9. Diz DI, Garcia-Espinosa MA, Gegick S, Tommasi EN, Ferrario CM, Tallant EA, Chappell MC, Gallagher PE. Injections of angiotensin-converting enzyme 2 inhibitor MLN4760 into nucleus tractus solitarii reduce baroreceptor reflex sensitivity for heart rate control in rats. Exp Physiol 93: 694-700, 2008.
10. Ferrario CM, Trask AJ, Jessup JA. Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol 289: H2281-H2290, 2005.
11. Garabelli PJ, Modrall JG, Penninger JM, Ferrario CM, Chappell MC. Distinct roles for angiotensin-converting enzyme 2 and carboxypeptidase A in the processing of angiotensins within the murine heart. Exp Physiol 93: 613-621, 2008.
12. Herath CB, Warner FJ, Lubel JS, Dean RG, Jia Z, Lew RA, Smith AI, Burrell LM, Angus PW. Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis. J Hepatol 47: 387-395, 2007.
13. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN, Phillips MJ, Portmann BG, Poulsen H, Scheuer PJ, Schmid M, Thaler H. Histological grading and staging of chronic hepatitis. J Hepatol 22: 696-699, 1995.
14. Iwata M, Cowling RT, Gurantz D, Moore C, Zhang S, Yuan JX, Greenberg BH. Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am J Physiol Heart Circ Physiol 289: H2356-H2363, 2005.
15. Jackson B, Cubela RB, Conway EL, Johnston CI. Lisinopril pharmacokinetics in chronic renal failure. Br J Clin Pharmacol 25: 719-724, 1988.
16. James J, Bosch KS, Aronson DC, Houtkooper JM. Sirius red histophotometry and spectrophotometry of sections in the assessment of the collagen content of liver tissue and its application in growing rat liver. Liver 10: 1-5, 1990.
17. Jandeleit-Dahm K, Lassila M, Davis BJ, Candido R, Johnston CI, Allen TJ, Burrell LM, Cooper ME. Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice. J Hypertens 23: 2071-2082, 2005.
18. Kubota E, Dean RG, Hubner RA, Casley DJ, Johnston CI, Burrell LM. Differential tissue and enzyme inhibitory effects of the vasopeptidase inhibitor omapatrilat in the rat. Clin Sci (Lond) 105: 339-345, 2003.
19. Li N, Zimpelmann J, Cheng K, Wilkins JA, Burns KD. The role of angiotensin converting enzyme 2 in the generation of angiotensin 1-7 by rat proximal tubules. Am J Physiol Renal Physiol 288: F353-F362, 2005.
20. Lubel JS, Herath CB, Burrell LM, Angus PW. Liver disease and the renin-angiotensin system: recent discoveries and clinical implications. J Gastroenterol Hepatol 23: 1327-1338, 2008.
21. Mendes AC, Ferreira AJ, Pinheiro SV, Santos RA. Chronic infusion of angiotensin-(1-7) reduces heart angiotensin II levels in rats. Regul Pept 125: 29-34, 2005.
22. Nascimento EA, Gioli-Pereira L, Carvalho LT, Santos EL, Pesquero JB, Kouyoumdjian M, Borges DR. Hemodynamic and metabolic effects of angiotensin II on the liver. Peptides 26: 315-322, 2005.
23. Paizis G, Tikellis C, Cooper ME, Schembri JM, Lew RA, Smith AI, Shaw T, Warner FJ, Zuilli A, Burrell LM, Angus PW. Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut 54: 1790-1796, 2005.
24. Raasch W, Dominiak P, Dendorfer A. Angiotensin I-converting enzyme-dependent and neutral endopeptidase-dependent generation and degradation of angiotensin II contrarily modulate noradrenaline release: implications for vasopeptidase-inhibitor therapy? J Hypertens 23: 1597-1604, 2005.
25. Rice GI, Thomas DA, Grant PJ, Turner AJ, Hooper NM. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J 383: 45-51, 2004.
26. Rockey DC. Vasoactive agents in intrahepatic portal hypertension and fibrogenesis: implications for therapy. Gastroenterology 118: 1261-1265, 2000.
27. Santos RA, Brosnihan KB, Jacobsen DW, DiCorleto PE, Ferrario CM. Production of angiotensin-(1-7) by human vascular endothelium. Hypertension 19: II56 -II61, 1992.
28. Schiavone MT, Santos RA, Brosnihan KB, Khosla MC, Ferrario CM. Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(1-7) heptapeptide. Proc Natl Acad Sci USA 85: 4095-4098, 1988.
29. Schindler C, Bramlage P, Kirch W, Ferrario CM. Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy. Vasc Health Risk Manag 3: 125-137, 2007.
30. Soler MJ, Wysocki J, Ye M, Lloveras J, Kanwar Y, Batlle D. ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice. Kidney Int 72: 614-623, 2007.
31. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275: 33238-33243, 2000.
32. Trask AJ, Averill DB, Ganten D, Chappell MC, Ferrario CM. Primary role of angiotensin-converting enzyme-2 in cardiac production of angiotensin-(1-7) in transgenic Ren-2 hypertensive rats. Am J Physiol Heart Circ Physiol 292: H3019-H3024, 2007.
33. Trask AJ, Ferrario CM. Angiotensin-(1-7): pharmacology and new perspectives in cardiovascular treatments. Cardiovasc Drug Rev 25: 162-174, 2007.
34. Trask AJ, Jessup JA, Chappell MC, Ferrario CM. Angiotensin-(1-12) is an alternate substrate for angiotensin peptide production in the heart. Am J Physiol Heart Circ Physiol 294: H2242-H2247, 2008.
35. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F, Acton S, Patane M, Nichols A, Tummino P. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 277: 14838-14843, 2002.
36. Warner FJ, Lubel JS, McCaughan GW, Angus PW. Liver fibrosis: a balance of ACEs? Clin Sci (Lond) 113: 109-118, 2007.
37. Warner FJ, Smith AI, Hooper NM, Turner AJ. Angiotensin-converting enzyme-2: a molecular and cellular perspective. Cell Mol Life Sci 61: 2704-2713, 2004.
38. Yamamoto K, Chappell MC, Brosnihan KB, Ferrario CM. In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.42411) in spontaneously hypertensive rats. Hypertension 19: 692-696, 1992.
39. Yang YY, Lin HC, Huang YT, Lee TY, Hou MC, Lee FY, Liu RS, Chang FY, Lee SD. Effect of 1-week losartan administration on bile duct-ligated cirrhotic rats with portal hypertension. J Hepatol 36: 600-606, 2002.